Bankers and executives had to work on Christmas Eve and New Year's Day, though they took a break for Christmas.
Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
Eli Lilly shares slide premarket on news of failed trial for sarcoma treatment
Weiterlesen »
Stocks making the biggest moves premarket: Tesla, CVS Health, Eli Lilly, Netflix & moreSome of the names on the move ahead of the open.
Weiterlesen »
Stocks making the biggest moves midday: Netflix, Boeing, Tesla, Eli Lilly & moreCheck out the companies making headlines midday Friday.
Weiterlesen »
Lilly cancer drug fails key trial, will no longer be prescribedEli Lilly and Co said on Friday that its cancer treatment Lartruvo, which had wo...
Weiterlesen »
Lilly's cancer therapy Lartruvo fails study, shares dropEli Lilly and Co said on Friday its cancer treatment Lartruvo, approved on an ac...
Weiterlesen »
Lilly eyes more cancer deals, but wary of CAR-T, gene therapyEli Lilly and Co remains in the hunt for cancer drugs even after announcing an $...
Weiterlesen »
Eli Lilly’s Sarcoma Drug Combo Proves Ineffective in TrialsEli Lilly said it would stop promoting Lartruvo, a relatively new cancer drug, after a study found it didn’t significantly prolong the lives of patients when used in combination with an older drug.
Weiterlesen »
House Democrats launch drug-pricing probe into a dozen major health-care companiesAbbVie, Amgen, AstraZeneca, Celgene, Eli Lilly, Johnson & Johnson, Mallinckrodt, Novartis, Novo Nordisk, Pfizer, Sanofi and Teva Pharmaceuticals received letters seeking detailed information and documents about the companies' pricing practices.
Weiterlesen »
From Amgen to Gilead, drugmakers are sitting on billions of cash — and top pharma executives are hinting about big M&A to come in 2019Billion-dollar deals from drug giants Eli Lilly & Co. and Bristol-Myers Squibb could set the tone for a year full of healthcare acquisitions.
Weiterlesen »